Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing.

导出 LinkOut

翻译打印收藏纠错

作者： Georgea R,Foley ^[1] ; James R,Marthick ^[1] ; Elaine A,Ostrander ^[2] ; Janet L,Stanford ^[3] ; Joanne L,Dickinson ^[1] ; Liesel M,FitzGerald ^[4]

作者单位： Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia. ^[1] Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA. ^[2] Fred Hutchinson Cancer Center, 1100 Fairview Ave. N., M4-B874, Seattle, WA 98109-1024, USA. ^[3] Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 7000, Australia. Electronic address: liesel.fitzgerald@utas.edu.au. ^[4]

主题词男(雄)性(Male);人类(Humans);基因检测(Genetic Testing);BRCA2蛋白质(BRCA2 Protein);前列腺肿瘤(Prostatic Neoplasms);突变(Mutation);生殖细胞系突变(Germ-Line Mutation);疾病遗传易感性(Genetic Predisposition to Disease)

DOI 10.1016/j.ejca.2022.11.034

PMID 36599183

发布时间 2023-03-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

European journal of cancer (Oxford, England

2023年180卷

155-157页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing.

European journal of cancer (Oxford, England

相似文献

European journal of cancer (Oxford, England

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Association of a novel BRCA2 mutation with prostate cancer risk further supports germline genetic testing.

European journal of cancer (Oxford, England

相似文献

European journal of cancer (Oxford, England

相关期刊

检索历史清除